Metastatic Bone Tumor
Conditions
Keywords
Biopsy-proven or clinically-obvious metastatic bone disease
Brief summary
This is a prospective, observational study designed to contribute data from patients with symptomatic metastatic bone disease treated at Sibley Memorial Hospital and Johns Hopkins Medicine to an international registry hosted by the Swedish Regional Cancer Centrum in Stockholm, Sweden. This protocol supports a worldwide effort to collect and store information from patients treated for symptomatic bone metastases within the International Skeletal Metastasis Registry (ISMR)
Detailed description
The registry is designed to update a suite of clinical decision-support tools designed for use when treating patients with metastatic bone disease. The models estimate the likelihood of survival at 1, 3, 6, 12, 18, and 24 months post surgery, which in turn, may be used for surgical decision-making.
Interventions
None listed
Sponsors
Study design
Eligibility
Inclusion criteria
* Adult patients, age 22 or older * Biopsy-proven or clinically-obvious metastatic bone disease * Symptomatic bone lesion requiring intervention o Including, not limited to, radiotherapy, cryotherapy, radiofrequency ablation, operative fixation, prosthetic replacement, amputation, or any combination of the above.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival (OS) | Up to 24 Months post surgery | OS (in months) calculated from the date of intervention. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Reoperation or retreatment for any reason | Up to 24 24 months post surgery | Number of participants with reoperation or retreatment for any reason. |
| Time to reoperation or retreatment for any reason | Up to 24 months post surgery | Timing of reoperation calculated from the date of intervention. |
Countries
United States